Evidence map›Paper›PMID 39611932›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study.

Samir Shaikh, Daksh Kunchala, Mansi Patel, Drishti Velecha, Suresh Prajapati, Reeshu Gupta

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Exploration of the Mechanism of Action ofJournal of hepatocellular carcinoma · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samir ShaikhParul Institute of Applied Sciences, Parul University, Vadodara, India.
Daksh KunchalaParul Institute of Applied Sciences, Parul University, Vadodara, India.
Mansi PatelCentre of Research for Development, Parul University, Vadodara, India.
Drishti VelechaParul Institute of Applied Sciences, Parul University, Vadodara, India.
Suresh PrajapatiParul Institute of Applied Sciences, Parul University, Vadodara, India.
Reeshu GuptaParul Institute of Applied Sciences, Parul University, Vadodara, India.ORCID 0000-0002-1743-4388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite standard therapies and immunotherapies, the mortality rate of patients with oral cancer remains high. Therefore, there is a need for more effective and targeted treatments. Multi-epitope vaccines have been developed for various cancers owing to their easy protection and delivery. However, no multi-epitope vaccine has been designed to prevent oral cancer.

methodsIn this study, a reverse vaccinology approach, along with various machine-learning integrated immunoinformatics tools, was used to design a multi-epitope peptide vaccine.

resultsUsing an integrated computational method, LYN Proto-Oncogene and AKT1 were identified as good candidates. Both LYN and AKT1 are protein kinases and plays a central role in regulating various outputs, such as proliferation, differentiation, apoptosis, and migration in cancer. These proteins were selected because of their favorable physicochemical properties, non-allergic, non-toxic, and antigenic nature. Suitable B and T cell epitopes were identified based on their physicochemical characteristics, toxicity, allergenicity, antigenicity, and immunogenicity. A vaccine was constructed using these immune epitopes and TLR4 agonist as an adjuvant. Molecular dynamics simulation suggests strong binding affinity for Toll-like receptor 4. Furthermore, immune simulation studies suggest the activation of immune cells and a strong IgG/IgM response for approximately one year.

conclusionWe propose that the vaccine developed has high immunogenic potential and able to induce both cell mediated and humoral immunity against oral cancer.

Indexed as

Cancer VaccinesComputational BiologyMouth NeoplasmsVaccines, SubunitComputer SimulationEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansImmunoinformaticsMolecular Dynamics SimulationProtein Subunit VaccinesProto-Oncogene MasProto-Oncogene Proteins c-aktVaccinologyCancer VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteMAS1 protein, humanProtein Subunit VaccinesProto-Oncogene MasProto-Oncogene Proteins c-aktVaccines, SubunitMolecular Dynamics Simulationmulti-peptide vaccineoral cancerreverse vaccinology

Identifiers

PMID39611932
PMCPMC11996101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.